The purpose of this document is to address the safety of donors and products involving Substances of Human Origin (SoHO) and the potential risk of thrombosis with thrombocytopenia adverse events following COVID-19 vaccination of a donor.
The 2020-2021 epidemic with a total of 3,555 reported HPAI detections and around 22,400,000 affected poultry birds in 28 European Countries appears to be one of the largest and most devastating HPAI epidemics ever occurred in Europe.
In 2018–2019, data on antimicrobial resistance in zoonotic and indicator bacteria, submitted by 28 EU Member States (MSs), were jointly analysed by the EFSA and the ECDC.
Between 8 December 2020 and 23 February 2021, 1,022 highly pathogenic avian influenza (HPAI) virus detections were reported in 25 EU/EEA countries and the UK in poultry (n=592), wild (n=421) and captive birds (n=9).
Between May 2018 and December 2020, 193 human cases of Salmonella Enteritidis sequence type (ST)11 were reported in Denmark (2), Finland (4), France (33), Germany (6), Ireland (12), the Netherlands (3), Poland (5), Sweden (6), and the United Kingdom (UK) (122). One in five cases was hospitalised. One death was reported. Fifty percent of the cases were children ≤ 18 years. The most recent case was reported by the UK in December 2020.
This report of the EFSA and ECDC presents the results of zoonoses monitoring activities carried out in 2019 in 36 European countries (28 Member States (MS) and eight non-MS).
Between 15 August and 7 December 2020, 561 highly pathogenic avian influenza (HPAI) virus detections were reported in 15 EU/EEA countries and UK in wild birds, poultry and captive birds, with Germany (n=370), Denmark (n=65), the Netherlands (n=57) being the most affected countries.
Since 16 October 2020, outbreaks of highly pathogenic avian influenza (HPAI) viruses have been reported in several EU/EEA countries – Belgium, Denmark, France, Germany, Ireland, the Netherlands, and Sweden as well as in the United Kingdom.
This report aims to identify and evaluate the operational challenges each country is facing in implementing vector control and to prioritise the needs to be addressed in order to facilitate national public health authorities in developing and/or enhancing their national WNV response capacities.